The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
β1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts
Open accessAbstract
β1 Integrin signaling has been shown to mediate cellular resistance to apoptosis after exposure to ionizing radiation (IR). Other signaling molecules that increase resistance include Akt, which promotes cell survival downstream of β1 integrin signaling. We previously showed that β1 integrin inhibitory antibodies (e.g., AIIB2) enhance apoptosis and decrease growth in human breast cancer cells in three-dimensional laminin-rich extracellular matrix (lrECM) cultures and in vivo. Here, we asked whether AIIB2 could synergize with IR to modify Akt-mediated IR resistance. We used three-dimensional lrECM cultures to test the optimal combination of AIIB2 with IR treatment of two breast cancer cell lines, MCF-7 and HMT3522-T4-2, as well as T4-2 myr-Akt breast cancer colonies or HMT3522-S-1, which form normal organotypic structures in three-dimensional lrECM. Colonies were assayed for apoptosis and β1 integrin/Akt signaling pathways were evaluated using Western blot. In addition, mice bearing MCF-7 xenografts were used to validate the findings in three-dimensional lrECM. We report that AIIB2 increased apoptosis optimally post-IR by down-regulating Akt in breast cancer colonies in three-dimensional lrECM. In vivo, addition of AIIB2 after IR significantly enhanced tumor growth inhibition and apoptosis compared with either treatment alone. Remarkably, the degree of tumor growth inhibition using AIIB2 plus 2 Gy radiation was similar to that of 8 Gy alone. We previously showed that AIIB2 had no discernible toxicity in mice; here, its addition allowed for a significant reduction in the IR dose that was necessary to achieve comparable growth inhibition and apoptosis in breast cancer xenografts in vivo. [Cancer Res 2008;68(11):4398–405]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antibodies against integrins β1, β6 and β8 were shown to selectively impair TGF-β1 activation85,313–315”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [315]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Giancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483
Self-citationWerb, Z., Tremble, P., Behrendtsen, O., Crowley, E., & Damsky, C. H. (1989) · The Journal of Cell Biology · doi:10.1083/jcb.109.2.877 · Cited by 1,057
Damiano, J. S., Cress, A. E., Hazlehurst, L., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 899
Brognard, J., Clark, A. S., Ni, Y., & Dennis, P. A. (2001) · PubMed · Cited by 885
The Akt-mTOR tango and its relevance to cancer
Hay, N. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.008 · Cited by 826
Weaver, V. M., Lelièvre, S. A., Lakins, J. N., Chrenek, M. A., Jones, J., Giancotti, F. G., Werb, Z., & Bissell, M. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00125-3 · Cited by 794
Self-citationWang, F., Weaver, V. M., Petersen, O. W., Larabell, C. A., Dedhar, S., Briand, P., Lupu, R., & Bissell, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14821 · Cited by 653
Self-citationPark, C. C., Mitsumori, M., Nixon, A. J., Recht, A., Connolly, J. L., Gelman, R. S., Silver, B., Hetelekidis, S., Abner, A. L., Harris, J. R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1668 · Cited by 547
Self-citation
Cited by
Sorted by citations
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
The Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Bissell, M. J., & Hines, W. C. (2011) · Nature Medicine · doi:10.1038/nm.2328 · Cited by 1,584
Self-citationEvery step of the way: integrins in cancer progression and metastasis
Hamidi, H., & Ivaska, J. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0038-z · Cited by 1,493
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Extracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. A. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 982
Inflammatory microenvironment remodelling by tumour cells after radiotherapy
McLaughlin, M., Patin, E. C., Pedersen, M., Wilkins, A. C., Dillon, M. T., Melcher, A. A., & Harrington, K. J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0246-1 · Cited by 921
Environment-mediated drug resistance: A major contributor to minimal residual disease
Meads, M. B., Gatenby, R. A., & Dalton, W. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2714 · Cited by 892
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 795
The tumor microenvironment is a dominant force in multidrug resistance
Correia, A. L., & Bissell, M. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.006 · Cited by 455
Self-citationTumor Microenvironment and Differential Responses to Therapy
Hirata, E., & Sahai, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026781 · Cited by 422
The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics
Prakash, J., & Shaked, Y. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0002 · Cited by 416
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Qin, T., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 406
Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins
Lovitt, C. J., Shelper, T., & Avery, V. M. (2018) · BMC Cancer · doi:10.1186/s12885-017-3953-6 · Cited by 358
Weigelt, B., Ghajar, C. M., & Bissell, M. J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.01.001 · Cited by 347
Self-citationWeigelt, B., Lo, A. T., Park, C. C., Gray, J. W., & Bissell, M. J. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0502-2 · Cited by 334
Self-citationFocal adhesion signaling and therapy resistance in cancer
Eke, I., & Cordes, N. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.07.009 · Cited by 339
TGF ‐β as a driver of fibrosis: physiological roles and therapeutic opportunities
Budi, E. H., Schaub, J. R., Decaris, M. L., Turner, S., & Derynck, R. (2021) · The Journal of Pathology · doi:10.1002/path.5680 · Cited by 310
Advanced Cell Culture Techniques for Cancer Drug Discovery
Lovitt, C. J., Shelper, T., & Avery, V. M. (2014) · Biology · doi:10.3390/biology3020345 · Cited by 292
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance
Ramos, P. M., & Bentires‐Alj, M. (2014) · Oncogene · doi:10.1038/onc.2014.314 · Cited by 287
Eke, I., Deuse, Y., Hehlgans, S., Gurtner, K., Krause, M., Baumann, M. A., Shevchenko, A., Sandfort, V., & Cordes, N. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61350 · Cited by 220
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W. Q., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 218
Integrin Signaling in Cancer Cell Survival and Chemoresistance
Aoudjit, F., & Vuori, K. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/283181 · Cited by 217
Pancreatic Stellate Cells Radioprotect Pancreatic Cancer Cells through β1-Integrin Signaling
Mantoni, T. S., Lunardi, S., Al‐Assar, O., Masamune, A., & Brunner, T. B. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1633 · Cited by 206
Cell-Matrix Interactions in Mammary Gland Development and Breast CancerPreprint
Muschler, J. L., & Streuli, C. H. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003202 · Cited by 215
Nam, J.-M., Onodera, Y., Bissell, M. J., & Park, C. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2319 · Cited by 196
Self-citationMetabolic crosstalk in the breast cancer microenvironment
Dias, A. S., Almeida, C. R., Helguero, L. A., & Duarte, I. F. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.002 · Cited by 206
Integrins in cancer: Emerging mechanisms and therapeutic opportunities
Liu, F., Wu, Q., Dong, Z., & Liu, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108458 · Cited by 202
Donlon, N., Power, R. F., Hayes, C., Reynolds, J. V., & Lysaght, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.045 · Cited by 199
Hongisto, V., Jernström, S., Fey, V., Mpindi, J.-P., Kleivi Sahlberg, K., Kallioniemi, O., & Perälä, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077232 · Cited by 181
β1-Integrin: A Potential Therapeutic Target in the Battle against Cancer Recurrence
Barkan, D., & Chambers, A. F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0642 · Cited by 181
Li, J. J. X., Tsang, J. Y., & Tse, G. M.-K. (2021) · Cancers · doi:10.3390/cancers13164233 · Cited by 190
Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma
Huang, R., & Rofstad, E. K. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0763-x · Cited by 183
The stromal compartments in pancreatic cancer: Are there any therapeutic targets?
Lunardi, S., Muschel, R. J., & Brunner, T. B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.039 · Cited by 178
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
Huang, C., Park, C. C., Hilsenbeck, S. G., Ward, R., Rimawi, M. F., Wang, Y.-C., Shou, J., Bissell, M. J., Osborne, C. K., & Schiff, R. (2011) · Breast Cancer Research · doi:10.1186/bcr2936 · Cited by 165
Self-citationCarbonell, W. S., DeLay, M., Jahangiri, A., Park, C. C., & Aghi, M. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0011 · Cited by 163
Self-citationThe Pathobiology of Collagens in Glioma
Payne, L. S., & Huang, P. H. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0236 · Cited by 146
Kim, H. S., Kim, S. C., Kim, S. J., Park, C. H., Jeung, H., Kim, Y. B., Ahn, J. B., Chung, H. C., & Rha, S. Y. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-348 · Cited by 135
Self-citationBioengineering 3D environments for cancer models
Alemany‐Ribes, M., & Semino, C. E. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.004 · Cited by 137
Radiobiology goes 3D: How ECM and cell morphology impact on cell survival after irradiation
Eke, I., & Cordes, N. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.06.007 · Cited by 140
Huck, L., Pontier, S. M., Zuo, D., & Muller, W. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003034107 · Cited by 131
Zschenker, O., Streichert, T., Hehlgans, S., & Cordes, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034279 · Cited by 129
Lander, V. E., Belle, J. I., Kingston, N. L., Herndon, J. M., Hogg, G. D., Liu, X., Kang, L.-I., Knolhoff, B. L., Bogner, S. J., Baer, J. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0192 · Cited by 114
Truong, H. H., Xiong, J., Ghotra, V. P. S., Nirmala, E., Haazen, L. C. J. M., Dévédec, S. E. L., Balcioglu, H. E., He, S., Snaar-Jagalska, E. B., Vreugdenhil, E., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004751 · Cited by 115
Krisnawan, V. E., Stanley, J. A., Schwarz, J. K., & DeNardo, D. G. (2020) · Cancers · doi:10.3390/cancers12102916 · Cited by 115
Hellevik, T., Pettersen, I., Berg, V., Winberg, J., Moe, B. T., Bartnes, K., Paulssen, R. H., Busund, L., Bremnes, R. M., Chalmers, A. J., et al. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-59 · Cited by 115
Active and inactive β1 integrins segregate into distinct nanoclusters in focal adhesions
Spiess, M., Hernández-Varas, P., Oddone, A., Olofsson, H., Blom, H., Waithe, D., Lock, J. G., Lakadamyali, M., & Strömblad, S. (2018) · The Journal of Cell Biology · doi:10.1083/jcb.201707075 · Cited by 111
Carbonic anhydrase IX: An atypical target for innovative therapies in cancer
Ronca, R., & Supuran, C. T. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189120 · Cited by 110
The impact of tumor stroma on drug response in breast cancer
Dittmer, J., & Leyh, B. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.006 · Cited by 107
The Extracellular, Cellular, and Nuclear Stiffness, a Trinity in the Cancer Resistome—A Review
Deville, S. S., & Cordes, N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01376 · Cited by 105
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
Li, J., Hu, J., Yang, Y., Zhang, H., Liu, Y., Fang, Y., Qu, L., Lin, A., Luo, P., Jiang, A., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00352-w · Cited by 120
Self-citationdos Santos, P. B., Zanetti, J. S., Ribeiro‐Silva, A., & Beltrão, E. I. U. F. D. P. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-104 · Cited by 101
Arya, A. D., Hallur, P. M., Karkisaval, A. G., Gudipati, A., Rajendiran, S., Dhavale, V., Ramachandran, B., Aravindakshan, J., Gundiah, N., & Chaubey, A. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b06309 · Cited by 99
PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1α
Eke, I., Koch, U., Hehlgans, S., Sandfort, V., Stanchi, F., Zips, D., Baumann, M. A., Shevchenko, A., Pilarsky, C. P., Haase, M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41078 · Cited by 96
Lahlou, H., & Muller, W. J. (2011) · Breast Cancer Research · doi:10.1186/bcr2905 · Cited by 96
Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells
Hehlgans, S., Eke, I., Storch, K., Haase, M., Baretton, G. B., & Cordes, N. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.07.004 · Cited by 94
Simultaneous β1 integrin-EGFR Targeting and Radiosensitization of Human Head and Neck Cancer
Eke, I., Zscheppang, K., Dickreuter, E., Hickmann, L., Mazzeo, E., Unger, K., Krause, M., & Cordes, N. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju419 · Cited by 95
Kirsch, D. G., Diehn, M., Kesarwala, A. H., Maity, A. M., Morgan, M. A., Schwarz, J. K., Bristow, R. G., Demaria, S., Eke, I., Griffin, R. J., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx231 · Cited by 96
Self-citationAhmed, K. M., Zhang, H., & Park, C. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3537 · Cited by 95
Self-citationThe CD10 Enzyme Is a Key Player to Identify and Regulate Human Mammary Stem Cells
Bachelard-Cascales, É., Chapellier, M., Delay, E., Pochon, G., Voeltzel, T., Puisieux, A., de Fromentel, C. C., & Maguer‐Satta, V. (2010) · Stem Cells · doi:10.1002/stem.435 · Cited by 97
Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer
Jahangiri, A., Nguyen, A. T., Chandra, A., Sidorov, M. K., Yagnik, G., Rick, J. W., Han, S. W., Chen, W. C., Flanigan, P. M., Schneidman‐Duhovny, D., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701821114 · Cited by 86
Self-citationCollective cancer invasion forms an integrin-dependent radioresistant niche
Haeger, A., Alexander, S., Vullings, M., Kaiser, F. M. P., Hulsbergen-Veelken, C. A. R., Flucke, U. E., Koehl, G. E., Hirschberg, M., Flentje, M. P., Hoffman, R. M., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20181184 · Cited by 86
Martínková, E., Maglott, A., Leger, D. Y., Bonnet, D., Stiborová, M., Takeda, K., Martin, S., & Dontenwill, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25187 · Cited by 81
Baltes, F., Pfeifer, V., Silbermann, K., Caspers, J., von Rekowski, K. W., Schlesinger, M., & Bendas, G. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118663 · Cited by 79
Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells
Dickreuter, E., Eke, I., Krause, M., Borgmann, K., van Vugt, M. A. T. M., & Cordes, N. (2015) · Oncogene · doi:10.1038/onc.2015.212 · Cited by 77
Carbonic Anhydrase IX (CAIX), Cancer, and Radiation Responsiveness
Ward, C., Meehan, J., Gray, M., Kunkler, I. H., Langdon, S. P., & Argyle, D. J. (2018) · Metabolites · doi:10.3390/metabo8010013 · Cited by 76
xCT inhibition sensitizes tumors to γ-radiation via glutathione reduction
Cobler, L., Zhang, H., Suri, P., Park, C., & Timmerman, L. (2018) · Oncotarget · doi:10.18632/oncotarget.25794 · Cited by 75
Self-citationA cell–ECM screening method to predict breast cancer metastasis
Barney, L. E., Dandley, E. C., Jansen, L. E., Reich, N. G., Mercurio, A. M., & Peyton, S. R. (2014) · Integrative Biology · doi:10.1039/c4ib00218k · Cited by 67
β1 and β4 integrins: from breast development to clinical practice
Nisticò, P., Modugno, F. D., Spada, S., & Bissell, M. J. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0459-x · Cited by 69
Self-citationDesmoplasia in Pancreatic Cancer. Can We Fight It?
Merika, E., Syrigos, K. N., & Saif, M. W. (2012) · Gastroenterology Research and Practice · doi:10.1155/2012/781765 · Cited by 68
Howe, G. A., & Addison, C. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20077 · Cited by 67
The cancer cell adhesion resistome: mechanisms, targeting and translational approaches
Dickreuter, E., & Cordes, N. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0326 · Cited by 67
Caromile, L. A., Dortche, K., Rahman, M., Grant, C. L., Stoddard, C. E., Ferrer, F. A., & Shapiro, L. H. (2017) · Science Signaling · doi:10.1126/scisignal.aag3326 · Cited by 67
Cancer-Associated Fibroblasts in Breast Cancer Treatment Response and Metastasis
Fernández‐Nogueira, P., Fuster, G., Gutiérrez-Uzquiza, Á., Gascón, P., Carbó, N., & Bragado, P. (2021) · Cancers · doi:10.3390/cancers13133146 · Cited by 59
How integrins control breast biology
Glukhova, M. A., & Streuli, C. H. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.06.010 · Cited by 59
Hou, S., Isaji, T., Hang, Q., Im, S., Fukuda, T., & Gu, J. (2016) · Scientific Reports · doi:10.1038/srep18430 · Cited by 60
β1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer
Yin, H., Wu, C., Lin, C., Chai, C., Hou, M., Chang, S., Tsai, H., Hung, W., Pan, M., & Luo, C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091432 · Cited by 57
Lee, M. Y., Lee, H., Seo, W. D., Park, K. H., & Lee, Y. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.11.022 · Cited by 56
Li, R., Shi, Y., Zhao, S., Shi, T., & Zhang, G. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.11.003 · Cited by 54
Cancer-Associated Fibroblasts: Implications for Cancer Therapy
Maia, A. R. R., & Wiemann, S. (2021) · Cancers · doi:10.3390/cancers13143526 · Cited by 58
Goel, H. L., Sayeed, A., Breen, M., Zarif, M. J., Garlick, D. S., Leav, I., Davis, R. J., FitzGerald, T. J., Morrione, A., Hsieh, C., et al. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24323 · Cited by 52
Xiang, X., Phung, Y., Feng, M., Nagashima, K., Zhang, J., Broaddus, V. C., Hassan, R., FitzGerald, D., & Ho, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014640 · Cited by 51
Hehlgans, S., Eke, I., & Cordes, N. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.01.065 · Cited by 51
β1 integrin targeting to enhance radiation therapy
Nam, J.-M., Chung, Y., Hsu, H. C., & Park, C. C. (2009) · International Journal of Radiation Biology · doi:10.3109/09553000903232876 · Cited by 52
Self-citationIdentifying and targeting tumor-initiating cells in the treatment of breast cancer
Wei, W., & Lewis, M. T. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0447 · Cited by 52
Caveolin-1: an essential modulator of cancer cell radio-and chemoresistance.
Hehlgans, S., & Cordes, N. (2011) · Europe PMC (PubMed Central) · Cited by 51
Isolation and characterization of squamous carcinoma cells resistant to photodynamic therapy
Sanabria, L. N. M., Cogno, I. S., Rodríguez, M. E., Sanz-Rodrı́guez, F., Zamarrón, A., Gilaberte, Y., Carrasco, E., Rivarola, V. A., & Juarranz, Á. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23145 · Cited by 52
Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy
Taeb, S., Ashrafizadeh, M., Zarrabi, A., Rezapoor, S., Musa, A. E., Farhood, B., & Najafi, M. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009622666211224154952 · Cited by 49
3D matrix-based cell cultures: Automated analysis of tumor cell survival and proliferation
Eke, I., Hehlgans, S., Sandfort, V., & Cordes, N. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3230 · Cited by 50
Integrin Signaling as a Cancer Drug Target
Danen, E. H. J. (2013) · ISRN Cell Biology · doi:10.1155/2013/135164 · Cited by 49
miR-134 suppresses the migration and invasion of non-small cell lung cancer by targeting ITGB1
Qin, Q., Wei, F., Zhang, J., & Li, B. (2017) · Oncology Reports · doi:10.3892/or.2017.5350 · Cited by 49
Dünker, N., & Jendrossek, V. (2019) · Cancers · doi:10.3390/cancers11101499 · Cited by 56
Robertson, C. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.11.009 · Cited by 45
The mesenchymal tumor microenvironment
Cukierman, E., & Bassi, D. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.20210 · Cited by 45
Miniaturized pre-clinical cancer models as research and diagnostic tools
Håkanson, M., Cukierman, E., & Charnley, M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.010 · Cited by 47
Metadata
- Authors
- Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J., & Bissell, M. J.
- Affiliations
- University of California, San Francisco (US)
- Lawrence Berkeley National Laboratory (US)
- Venue
- Cancer Research
- Published
- 2008-06-01
- Volume
- 68
- Issue
- 11
- Pages
- 4398-4405
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3719863
- OpenAlex
- W1968324001
- Cited by
- 220
- References
- 43
- Citations by year
- 2026: 6 · 2025: 3 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 15 · 2020: 9 · 2019: 10 · 2018: 12 · 2017: 14 · 2016: 13 · 2015: 13 · 2014: 20 · 2013: 19 · 2012: 18
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- U.S. Department of Defense (DE-AC02-05CH11231)
- U.S. Department of Energy (-AC02-05CH11231, DE-AC03-?, AC03-76SF00098, DEAC03-76SF00098, 05CH11231, DE AC02 05CH11231, DE-AC02-)
- National Institutes of Health (DE-AC02–05CH11231, NIH P50, DE-AC03- 76SF00098)
- University of California, San Francisco
- National Cancer Institute (R01CA124891, CA64786-09, CA-58207, R37CA064786, P50CA058207, R01CA064786, CA CA58207-08, DE-AC02-05CH11231)
- Biological and Environmental Research (05CH11231, DE-AC02 − 05CH11231, AC02-05CH11231)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Cell Adhesion Molecules Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- beta1 integrin, radiotherapy, breast cancer, Akt signaling, radioresistance (biology), apoptosis, MCF-7 xenografts, tumor growth inhibition, radiosensitization
- MeSH terms
- Breast, Breast Neoplasms, Cell Line, Cell Separation, Humans, Transplantation, Heterologous, Blotting, Western, Treatment Outcome, Apoptosis, Microscopy, Confocal, Integrin beta1, In Situ Nick-End Labeling, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
